Purple Biotech (US:PPBT) — Company Overview, News & Financial Data
Purple Biotech focuses on developing innovative cancer therapies that target treatment resistance and improve patient outcomes.
Purple Biotech
Purple Biotech (TLV:PPBT), (NASDAQ:PPBT) is a biotechnology company focused on advancing various cancer therapies that target the challenges of resistance to treatments. With a pipeline that includes development-stage drugs aimed at providing new options for cancer patients, Purple Biotech's projects predominantly revolve around creating innovative, targeted therapies. The company's objective is to improve patient outcomes by exploring pathways and mechanisms that can overcome tumor resistance and reduce side effects, making cancer treatments more effective and tolerable. Purple Biotech is solely listed on the NASDAQ stock exchange under the symbol PPBT, highlighting its commitment to research and development in the oncology sector.
Snapshot
Operations
Products and/or services of Purple Biotech
- NT219, a small molecule targeting treatment-resistant cancer pathways.
- CM24, a monoclonal antibody inhibiting CEACAM1 for various cancers.
- Research partnership for developing novel cancer therapies.
- Collaboration on drug discovery and development in oncology.
- Involvement in early-stage research on tumor microenvironment targeted therapies.
- Expertise in kinase inhibitor technology for cancer treatment.
Purple Biotech executive team
- Mr. Gil Efron CPA, M.A.Chief Executive Officer
- Dr. Michael Schickler Ph.D.Head of Clinical & Regulatory Affairs
- Mr. Shai Lankry CPA, M.B.A.Chief Financial Officer